Friday 6 November 2026 Export EXEL’s income statement to Excel — free account

Exelixis, Inc.

EXEL Healthcare Biotechnology

Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.

Revenue: +10.2%
EPS: +22.2%
Free cash flow: −4.83%

Quarter to September 2026, against a year earlier

Revenue growth 10 yrs

69.96 1.25 +1.82%

Follow EXEL

Alert me

Market cap: $16.8B
P/E: 19.9×
Fwd P/E: 20.2×
Dividend yield: —
F-score: 7/9
Altman Z: 12.68
Beneish M: −2.61
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Exelixis, Inc. (EXEL) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Exelixis, Inc. (EXEL) trades at a P/B ratio of 9.3×. Over the past ten years it has ranged from 0.0× (September 2016) to 146× (December 2016); the current reading is higher than 86% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/EXEL/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Exelixis, Inc. P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/EXEL/metrics/pb-ratio">Exelixis, Inc. (EXEL) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	5.5×	27.97%
FY2024	4.3×	27.97%
FY2023	3.4×	59.67%
FY2022	2.1×	(19.11%)
FY2021	2.6×	(20.92%)
FY2020	3.3×	4.12%
FY2019	3.2×	(30.52%)
FY2018	4.6×	(85.93%)
FY2017	32.4×	(21.70%)
FY2016	41.3×	—

Period	P/B ratio	Change
Sep 2026	7.9×	6.19%
Jun 2026	7.4×	29.31%
Mar 2026	5.7×	3.93%
Dec 2025	5.5×	7.34%
43 more quarters	Free account

Against its own ten years

Low 0.0× High 146×

Ten-year median 3.6×

Current reading's percentile 84

Company	P/B ratio
HALO Halozyme Therapeutics, Inc. compare	n/m
BBIO BridgeBio Pharma, Inc. compare	n/m
BNTX BioNTech SE Sponsored ADR compare	1.1×
JAZZ Jazz Pharmaceuticals PLC compare	3.5×
ALNY Alnylam Pharmaceuticals, Inc. compare	5.8×
EXEL Exelixis, Inc.	9.3×
ASND Ascendis Pharma A/S compare	9.8×
SMMT Summit Therapeutics PLC compare	17.8×
INSM Insmed, Inc. compare	32.6×
Biotechnology industry median	2.0×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Exelixis, Inc. (EXEL) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on EXEL

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on EXEL

Stockrow Weekly